Astal Laboratories Limited has announced a substantial equity investment through the allotment of 29,56,666 shares to non-promoter investors under a preferential allotment arrangement. The transaction, completed on January 14, 2026, represents a significant capital infusion for the pharmaceutical company.

Share Allotment Details

The preferential allotment was made to two non-promoter investors through a share swap mechanism. The distribution of shares and their impact on shareholding is detailed below:

Both investors previously held zero shares in the company, making this their initial investment in Astal Laboratories. The allotment was made pursuant to SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Capital Structure Transformation

The preferential allotment has significantly altered the company's capital structure. The equity share capital witnessed substantial growth following this transaction:

The transaction represents an investment of approximately ₹29.57 crores based on the face value of ₹10 per share, demonstrating significant investor confidence in the company's prospects.

Regulatory Compliance

Astal Laboratories has fulfilled all regulatory requirements under SEBI regulations. The company submitted the necessary disclosures to BSE Limited on January 19, 2026, through Company Secretary Mahendra Kumar. The disclosure was made in the prescribed format under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The share swap arrangement facilitated this preferential allotment, indicating a strategic transaction rather than a cash-based investment. This method of capital raising suggests potential synergies or strategic partnerships between the parties involved.

Company Profile

Astal Laboratories Limited, formerly known as Macro International Limited, operates from its registered office in Noida, Uttar Pradesh, with corporate offices in Telangana. The company trades on BSE Limited under scrip code 512600 with the security ID ASTALLTD. The pharmaceutical company has been incorporated since 1993 and maintains its focus on laboratory and pharmaceutical operations.

Astal laboratories has disclosed a substantial share acquisition by investor Sesha Sai Nikhil Chintalapati through preferential allotment. The company received the mandatory disclosure under SEBI regulations on January 19, 2026, regarding the significant increase in shareholding by the non-promoter investor.

Share Acquisition Details

Sesha Sai Nikhil Chintalapati acquired 48,67,348 equity shares on January 14, 2026, through preferential allotment pursuant to a share swap arrangement. The acquisition represents a substantial increase in his stake in the pharmaceutical company.

Regulatory Compliance

The disclosure was made pursuant to Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Chintalapati belongs to the non-promoter group of Astal Laboratories Limited and submitted the required documentation to both BSE Limited and the company on January 16, 2026.

The transaction involved persons acting in concert, including Venkata Ramchandra Murthy Chintalapati, who maintained his existing holding of 2,507 shares (0.01% of voting capital) without any changes during this acquisition.

Impact on Share Capital Structure

The preferential allotment significantly altered the company's equity structure:

Company Information

Astal Laboratories Limited, formerly known as Macro International Limited, is listed on BSE with scrip code 512600 and security ID ASTALLTD. The company operates from its registered office in Noida, Uttar Pradesh, with corporate office located in Hyderabad, Telangana.

The disclosure was signed by Company Secretary and Compliance Officer Mahendra Kumar (Membership No. A71224) and submitted to BSE Limited's Corporate Relationship Department for record maintenance.